For Immediate Release – October 7, 2020.
Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a
pharmaceutical company focused on the research, development and commercialization of
oncology and antiviral drugs today announced that it has screened and subsequently identified
a lead compound from its library of Coronavirus protease inhibitors. The screening which
pinpointed the lead compound was performed at the University of Georgia, College of Pharmacy
under the leadership of Dr. Scott D. Pegan, Director of the Center for Drug Discovery and
Interim Associate Head of Pharmaceutical and Biomedical Sciences. The Company is currently
looking into expanding its collaboration with the University of Georgia and will be seeking the
University’s assistance in advancing the development of the newly identified lead compound.
The compounds which were screened are based on the technology described in Sunshine
Biopharma’s recently filed patent application covering small molecules which can be used to
treat Coronavirus infections. Next, Sunshine’s lead compound will be put through a battery of in
vitro tests to evaluate its specific inhibitory activity against the SARS-CoV-2 papain-like
protease (PLpro), one of two virus encoded proteases essential for viral replication. In addition
to cleaving the virus encoded polyprotein at three different sites to generate mature virus
proteins, PLpro also cleaves certain host proteins resulting in suppression of the host immune
response and allowing virus replication to proceed unchecked which enhances the virus’ ability
to cause severe morbidity. Following the in vitro tests, the lead compound will be moved forward
to the cell culture testing stage followed by mice studies before entering human clinical trials.
About Sunshine Biopharma’s Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of
COVID-19, the current ongoing pandemic that has claimed the lives of over 1,000,000 people
worldwide since it first appeared in December 2019. There are currently no drugs that can
effectively arrest replication of the virus in people who have contracted the illness. On May 22,
2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which
were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to
multiply and cause illness.
About the University of Georgia
As part of its land grant tripartite mission, the University of Georgia is committed to
creating and applying new knowledge for the public good. UGA’s Center for Drug Discovery as
well as the Colleges of Pharmacy are excited to be a part of this ground-breaking research
related to discovery of new treatment options for COVID-19. Profs. Scott Pegan, and David
Crich will be working with Sunshine Biopharma to spearhead the study of novel therapeutics for
the prevention and spread of COVID-19. This interdisciplinary effort involves state of the art
approaches in chemical synthesis and drug screening. This continues University of Georgia’s
long-standing tradition in translating scientific breakthroughs to address real world health
concerns.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to
date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant
Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer
cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to
be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and
assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ
materially from those anticipated or expected, including statements related to the amount and timing of expected
revenues statements related to our financial performance, expected income, distributions, and future growth for
upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by
the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain
events could differ materially from those projected in or contemplated by the forward-looking statements due to a
number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock
market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC
filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as
new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the
near and long term. Additional service offerings may expose us to additional legal and regulatory costs and
unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of
which cannot be predicted at this time.
For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com